MASSAIA, Massimo Giovanni Stefano
 Distribuzione geografica
Continente #
NA - Nord America 7758
EU - Europa 7094
AS - Asia 2986
AF - Africa 151
SA - Sud America 59
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 29
Totale 18123
Nazione #
US - Stati Uniti d'America 7599
CN - Cina 2141
DE - Germania 1075
SE - Svezia 1004
IT - Italia 934
IE - Irlanda 878
UA - Ucraina 771
FR - Francia 627
FI - Finlandia 437
AT - Austria 433
KR - Corea 363
GB - Regno Unito 289
PL - Polonia 223
VN - Vietnam 158
CA - Canada 134
SN - Senegal 112
IN - India 99
BE - Belgio 60
DK - Danimarca 58
JP - Giappone 57
NL - Olanda 51
GR - Grecia 50
RU - Federazione Russa 45
AU - Australia 42
BR - Brasile 31
EU - Europa 26
BY - Bielorussia 25
CH - Svizzera 23
ES - Italia 22
HK - Hong Kong 22
UZ - Uzbekistan 22
TR - Turchia 21
MX - Messico 19
TW - Taiwan 19
PT - Portogallo 18
SG - Singapore 14
NO - Norvegia 13
ZA - Sudafrica 13
MU - Mauritius 12
RO - Romania 12
SA - Arabia Saudita 11
TH - Thailandia 11
CL - Cile 9
IR - Iran 9
RS - Serbia 9
CZ - Repubblica Ceca 8
ID - Indonesia 8
MK - Macedonia 8
CO - Colombia 7
LU - Lussemburgo 6
PK - Pakistan 6
AR - Argentina 5
EG - Egitto 5
HU - Ungheria 5
IL - Israele 5
PE - Perù 5
DZ - Algeria 4
NZ - Nuova Zelanda 4
HR - Croazia 3
KZ - Kazakistan 3
MA - Marocco 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
AP - ???statistics.table.value.countryCode.AP??? 2
CU - Cuba 2
HN - Honduras 2
IQ - Iraq 2
LV - Lettonia 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
A1 - ???statistics.table.value.countryCode.A1??? 1
BD - Bangladesh 1
BG - Bulgaria 1
BW - Botswana 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
GI - Gibilterra 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MO - Macao, regione amministrativa speciale della Cina 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
QA - Qatar 1
UY - Uruguay 1
ZW - Zimbabwe 1
Totale 18123
Città #
Beijing 1694
Chandler 1226
Dublin 875
Jacksonville 521
Houston 446
Vienna 430
Ann Arbor 410
Villeurbanne 355
Medford 322
Nyköping 318
Fairfield 298
Dearborn 290
Princeton 281
Wilmington 264
Torino 226
Warsaw 213
Woodbridge 191
San Mateo 182
Ashburn 153
Redwood City 125
Seattle 121
Fremont 117
Milan 112
Cambridge 105
Pisa 96
Dong Ket 93
Boston 79
Boardman 76
Toronto 67
Turin 62
Munich 56
Brussels 50
Shanghai 50
Düsseldorf 44
Hefei 42
Norwalk 40
Nanjing 37
Falls Church 36
Verona 36
Nürnberg 35
Mountain View 32
Guangzhou 30
New York 28
Rome 28
Hangzhou 27
Phoenix 27
Lachine 26
Kunming 25
Tokyo 25
Chengdu 24
Paris 24
San Diego 24
Philadelphia 21
Raritan 20
Jinan 16
Hebei 15
Taipei 15
Duncan 14
Nanchang 14
Dallas 13
Changsha 12
Des Moines 12
Ottawa 12
Wuhan 12
San Jose 11
Shenyang 11
Central District 10
Hanover 10
Hyderabad 10
London 10
Piemonte 10
Bologna 9
Chennai 9
Den Haag 9
Florence 9
Leawood 9
Mexico 9
Zhengzhou 9
Fuzhou 8
Lisbon 8
Mcallen 8
Provo 8
Rotterdam 8
Seoul 8
Upper Marlboro 8
Chongqing 7
Detroit 7
Istanbul 7
Marseille 7
Montréal 7
Palermo 7
Silver Spring 7
Tucson 7
Bengaluru 6
Bogotá 6
Delhi 6
Jakarta 6
Kharkiv 6
Liverpool 6
Menlo Park 6
Totale 10959
Nome #
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) 398
Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients 356
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia 303
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 276
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 246
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. 241
Chicago 2014 - 30 years of γδ T cells 230
The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vγ9Vδ2 T cell activation by dendritic cells 230
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 186
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO) 184
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) 171
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 169
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile 165
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 164
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 150
null 148
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer 146
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 142
Amplification of T cell activation induced by CD73 (ecto-5' nucleotidase) engagement. 126
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 126
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 117
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. 117
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 115
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 114
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 110
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 108
Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression 108
ABCA1, apoA-I, and BTN3A1: A Legitimate ménage à trois in dendritic cells 108
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia 108
Vγ9Vδ2 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma 108
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 106
Effective anti-tumor immunomodulatory properties of zoledronic acid 104
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. 104
Multiple myeloma: altered CD4/CD8 ratio in bone marrow. 103
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 102
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 100
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 100
Refractory cytopenia with multilinear dysplasia (RCMD) in patient with Fanconi anaemia 99
The tryptophan metabolism in the immune dysregulation of multiple myeloma 99
Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. 98
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 97
Is there a role for allografting in myeloma ?: an update of a comparative study 96
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 94
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 93
CD157 reduces acutemyeloid leukemia cell sensitivity tocytarabine through upregulation of MCL-1 anti-apoptotic protein 92
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 91
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 91
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 91
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 91
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL 91
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 90
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 90
CD157 REGULATES THE SENSITIVITY OF ACUTE MYELOID LEUKEMIA CELLS TO CHEMOTHERAPY BY MODULATING THE APOPTOTIC RESPONSE 90
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 88
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 88
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 86
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 86
Difference in polyamine transport in human B and T lymphocytes. 84
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 84
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells 84
Cytobiological studies in multiple myeloma. 83
Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies. 83
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 83
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 82
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 82
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 81
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 81
The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells 80
Cyclosporin A and dipyridamole: an effective combination against the generation of cytotoxic T lymphocytes (CTL). 80
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 80
null 80
Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. 80
Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. 79
[Idiotypic study of human myeloma] 79
Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter. 77
Monoclonal immunoglobulin gene rearrangement in peripheral lymphocytes of a patient with multiple myeloma. 77
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 77
TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS 77
Comparison of purine degradative enzymes and terminal deoxynucleotidyl transferase in T cell leukaemias and in normal thymic and post-thymic T cells. 76
Changes in SRBC binding capacity and T-surface antigen expression on human peripheral blood lymphocytes stimulated by 12-0-tetradecanoilphorbol-13-acetate (TPA). 76
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 76
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 76
A Score-Based Approach to18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility 75
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 75
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells 75
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 75
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 74
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies:correlation with diagnosis and disease status. 74
B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes. 74
Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. 73
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 73
CD38 stimulation lowers the activation threshold and enhances the alloreactivity of cord blood T cells by activating the phosphatidylinositol 3-kinase pathway and inducing CD73 expression. 72
Human myeloma: several subsets of circulating lymphocytes express plasma cell-associated antigens. 72
Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. 72
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 72
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 72
[Prognostic factors in multiple myeloma] 71
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. 71
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 71
Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. 70
Totale 11138
Categoria #
all - tutte 35422
article - articoli 0
book - libri 0
conference - conferenze 13533
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48955


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201871 0000 00 00 00071
2018/20191736 60468841 102155 98273 98200390185
2019/20202601 79117147250 202461 360152 221252207153
2020/20212693 271155170156 291125 175134 321209377309
2021/20223011 1088991218 12357 463159 104326648625
2022/20233930 41532193347 353997 365265 4291352100
Totale 18958